AbbVie expects Q4 2022 $243M acquired IPR&D charge, cutting adjusted EPS by $0.14

AbbVie Inc.

2022-FY EPS reported $6.63 revenue$58,054,000,000

Q4 2022 acquired IPR&D and milestones expense of $243M pre-tax; $0.14 hit to GAAP and adjusted EPS.
Q4 2022 adjusted EPS guidance revised to $3.51-$3.55 from prior $3.65-$3.69.
Full-year 2022 adjusted EPS guidance revised to $13.70-$13.74 from prior $13.84-$13.88.
Results are preliminary and subject to financial statement closing procedures.
AbbVie does not forecast acquired IPR&D expense due to transaction uncertainty.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbbVie Inc. reported the quarter ended December 31, 2022 results: EPS $3.51 - $3.55. Guidance reaffirmed.

Period: the quarter ended December 31, 2022
EPS: $3.51 - $3.55
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

AbbVie’s fourth quarter 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $3.51 - $3.55.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbbVie Inc. reported the full-year ended December 31, 2022 results: EPS $13.70 - $13.74. Guidance reaffirmed.

Period: the full-year ended December 31, 2022
EPS: $13.70 - $13.74
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

AbbVie’s full-year 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $13.70 - $13.74.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.